Publications by authors named "B S Makwana"
Background: Specific cancer treatments can lead to cancer therapy-related cardiac dysfunction (CTRCD). Sodium glucose cotransporter-2 inhibitors (SGLT2is) can potentially prevent these cardiotoxic effects.
Objectives: This study sought to determine whether SGLT2i use is associated with a lower incidence of CTRCD in patients with type 2 diabetes mellitus (T2DM) and cancer, exposed to potentially cardiotoxic antineoplastic agents, and without a prior documented history of cardiomyopathy or heart failure.
Introduction: Immunotherapy has transformed cancer treatment, particularly with immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy. Despite their efficacy, these therapies can induce cardiotoxicity, presenting significant clinical challenges. Immune checkpoint inhibitors can cause myocarditis; pericarditis; arrhythmias; and myocardial infarction through immune-mediated inflammation.
View Article and Find Full Text PDFBackground: Guidelines recommend palliative care (PC) for patients with heart failure. However, little research has been performed assessing the effect of PC consultation in patients with heart failure with preserved ejection fraction (HFpEF).
Objectives: The purpose of this study was to investigate the impact of PC consultation on symptom burden and health care utilization among individuals with HFpEF during the last 3 years of their lives.
Article Synopsis
- - Immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy have drastically improved cancer treatment but can lead to serious cardiovascular issues, notably myocarditis.
- - Diagnosis of ICI-myocarditis involves using a combination of biomarkers, imaging, and endomyocardial biopsy, while cytokine release syndrome (CRS) presents similar symptoms to distributive shock.
- - Effective management includes stopping the offending therapy, providing immunosuppression with corticosteroids for ICI-myocarditis, and using interleukin-6 antagonists for CRS, requiring close collaboration between oncologists and cardiologists for optimal care.
Article Synopsis
- - The study explores the additional benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RA) for patients with obesity, type 2 diabetes, and heart failure with preserved ejection fraction (HFpEF) who are already on sodium-glucose cotransporter 2 inhibitors (SGLT2i).
- - Researchers analyzed data from over 7,000 patients and found that those taking both GLP-1 RA and SGLT2i had significantly lower risks of heart failure exacerbations and other health issues compared to those on SGLT2i alone.
- - While the combination therapy showed many benefits, it also had an increased risk of diabetic retinopathy, indicating the need for